SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code:
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 8.01|| |
On August 21, 2020, Endo International plc (the “Company”) issued a press release announcing the expiration and final tender results of the cash tender offer (the “Offer”) made by Endo Finance LLC (“Endo Finance”), a wholly-owned subsidiary of the Company, for any and all of Endo Finance’s outstanding $182,479,000 aggregate principal amount of 5.75% Senior Notes due 2022 (the “Notes”). The Offer expired at 5:00 p.m., New York City time, on August 21, 2020.
On August 26, 2020 (the “Payment Date”), Endo Finance paid all holders of such Notes $950 per $1,000 principal amount for all Notes accepted in the Offer, including accrued and unpaid interest from the July 15, 2020 interest payment date to, but not including, the Payment Date. All Notes purchased on the Payment Date have been subsequently retired.
A copy of the press release announcing the expiration and final results of the Offer is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Press release dated August 21, 2020, announcing the expiration and final results of the Offer.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|ENDO INTERNATIONAL PLC|
|Matthew J. Maletta|
|Executive Vice President,|
|Chief Legal Officer and Company Secretary|
Date: August 26, 2020
ENDO INTERNATIONAL PLC ANNOUNCES THE EXPIRATION AND FINAL TENDER RESULTS
OF ITS PREVIOUSLY ANNOUNCED TENDER OFFER
DUBLIN, August 21, 2020 Endo International plc (the Company) (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the Offer) by its wholly owned subsidiary Endo Finance LLC (Endo Finance) for any and all of its outstanding 5.75% Senior Notes due 2022 (the Notes), which expired at 5:00 p.m., New York City time, on August 21, 2020 (the Expiration Time).
As of the Expiration Time, $10,431,000 aggregate principal amount of Notes, or approximately 5.72% of the aggregate principal amount of Notes outstanding, had been validly tendered and not validly withdrawn. There are no Notes that remain subject to guaranteed delivery procedures. The complete terms and conditions of the Offer were set forth in the Offer to Purchase, dated August 17, 2020 (the Offer to Purchase), and the related Notice of Guaranteed Delivery (together with the Offer to Purchase, the Offer Documents).
Endo Finance expects to accept for payment all Notes validly tendered and not validly withdrawn prior to the Expiration Time and, in accordance with the terms of the Offer to Purchase, will pay all holders of such Notes $950 per $1,000 principal amount for all Notes accepted in the Offer on August 26, 2020 (the Payment Date), including those properly tendered and not validly withdrawn prior to the Expiration Time and those tendered by the guaranteed delivery procedures described within the Offer to Purchase within two business days after the Expiration Time. Also, on the Payment Date, Endo Finance will pay accrued and unpaid interest from the July 15, 2020 interest payment date to, but not including, the Payment Date. For avoidance of doubt, interest on the Notes will cease to accrue on the Payment Date for all Notes accepted in the Offer. All Notes purchased on the Payment Date will subsequently be retired.
D.F. King & Co., Inc. was the information agent and tender agent for the Offer.
This press release shall not constitute an offer to buy or a solicitation of an offer to sell any Notes. The Offer was made solely pursuant to the Offer Documents. The Offer was not made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Learn more at www.endo.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the relevant Canadian securities legislation, including, but not limited to, the statements regarding the settlement timing of the Offer. Statements including words such as believes, expects, anticipates, intends, estimates, plan, will, may, look forward, intend, guidance, future or similar expressions are forward-looking statements. Because these statements reflect Endos current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers
should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, including those risks related to our ability to consummate the Offer on the terms described herein and on the time period described or at all and such other factors as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption Risk Factors in Endos latest Form 10-K and subsequent Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endos future results and could cause Endos actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
CONTACT: Media: Heather Zoumas-Lubeski, (484) 216-6829, email@example.com; Investors: Pravesh Khandelwal, (845)-364-4833, firstname.lastname@example.org